Department of Precision Medicine, School of Medicine, Sungkyunkwan University (SKKU), Suwon, 16419, Republic of Korea.
Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, 06351, Republic of Korea.
Mamm Genome. 2021 Aug;32(4):206-222. doi: 10.1007/s00335-021-09859-3. Epub 2021 Mar 1.
Accumulating evidence has revealed the link between the microbiota and various human diseases. Advances in high-throughput sequencing technologies have identified some consistent disease-associated microbial features, leading to the emerging concept of microbiome-based therapeutics. However, it is also becoming clear that there are considerable variations in the microbiota among patients with the same disease. Variations in the microbial composition and function contribute to substantial differences in metabolic status of the host via production of a myriad of biochemically and functionally different microbial metabolites. Indeed, compelling evidence indicates that individuality of the microbiome may result in individualized responses to microbiome-based therapeutics and other interventions. Mechanistic understanding of the role of the microbiota in diseases and drug metabolism would help us to identify causal relationships and thus guide the development of microbiome-based precision or personalized medicine. In this review, we provide an overview of current efforts to use microbiome-based interventions for the treatment of diseases such as cancer, neurological disorders, and diabetes to approach precision medicine.
越来越多的证据揭示了微生物组与各种人类疾病之间的联系。高通量测序技术的进步已经确定了一些与疾病相关的微生物特征,从而产生了基于微生物组的治疗方法的新兴概念。然而,同样清楚的是,患有相同疾病的患者之间的微生物组存在很大差异。微生物组成和功能的变化通过产生大量生化和功能不同的微生物代谢物,对宿主的代谢状态产生重大影响。事实上,有强有力的证据表明,微生物组的个体性可能导致对基于微生物组的治疗方法和其他干预措施的个体化反应。对微生物组在疾病和药物代谢中的作用的机制理解将帮助我们识别因果关系,从而指导基于微生物组的精准或个性化医学的发展。在这篇综述中,我们概述了目前利用基于微生物组的干预措施来治疗癌症、神经紊乱和糖尿病等疾病以实现精准医学的努力。